What is the recommended protocol for using intravenous (IV) ketamine for treating major depressive disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

IV Ketamine Protocol for Major Depressive Disorder

IV ketamine should be reserved for patients with major depressive disorder who have not responded to several adequate pharmacologic trials, with a recommended protocol of 0.5 mg/kg administered intravenously over 40 minutes. 1

Patient Selection

  • Ketamine is not recommended as initial treatment for major depressive disorder but should be reserved for patients who have failed or not tolerated previous therapies 1
  • Best candidates are those with treatment-resistant depression (TRD), defined as failure to respond to at least two adequate trials of antidepressant medications 1, 2
  • Consider ketamine for patients with severe depression accompanied by suicidal ideation, as it has demonstrated rapid reduction in suicidal thoughts 1, 2

Dosing Protocol

  • Standard dose: 0.5 mg/kg administered intravenously over 40 minutes 1, 2
  • Administration should be performed by or under the direction of physicians experienced in administering general anesthetics and maintaining a patent airway 3
  • For maintenance of antidepressant effect, ketamine can be administered by slow microdrip infusion at 0.1 to 0.5 mg/minute 3

Preparation and Administration

  • For IV administration, the 100 mg/mL concentration must be properly diluted before use 3
  • Dilute with an equal volume of either Sterile Water for injection, 0.9% Sodium Chloride Injection, or 5% Dextrose in Water 3
  • Use immediately after dilution 3
  • For maintenance infusions, prepare a dilute solution containing 1 mg of ketamine per mL by transferring 10 mL from a 50 mg/mL vial (or 5 mL from a 100 mg/mL vial) to 500 mL of appropriate diluent 3

Treatment Schedule

  • Initial treatment typically involves a single infusion, with effects appearing within 24 hours and lasting 3-7 days 2, 4
  • For sustained benefit, a series of 6 infusions administered three times weekly over a 12-day period has shown efficacy 5
  • After initial series, maintenance infusions can be spaced out, with frequency decreasing from every 5 days to every 3-4 weeks over the first 5 months 6

Monitoring and Safety Considerations

  • Continuous vital sign monitoring is essential during and immediately after infusion 3
  • Emergency airway equipment must be immediately available 3
  • Consider administering an antisialagogue prior to ketamine administration due to potential for increased salivation 3
  • Monitor for psychotomimetic experiences, dissociative symptoms, and hypertension 2, 7
  • Consider augmenting with a benzodiazepine to prevent neuropsychological manifestations during emergence 3

Expected Outcomes

  • Rapid improvement in depressive symptoms can occur within hours to 1 day after infusion 2, 4
  • Antidepressant effects typically last 3-7 days after a single infusion 1, 4
  • When used as adjunctive therapy to ongoing antidepressant treatment, effects may persist longer than when used as monotherapy 1
  • In clinical practice, approximately 26% of patients achieve response (50% improvement) and 15% achieve remission after 6 weeks of treatment 6

Important Limitations and Caveats

  • Ketamine lacks long-term efficacy and safety trials in major depressive disorder 1
  • The VA/DoD Clinical Practice Guideline is the only major guideline that addresses ketamine use for depression 1
  • Patients should be informed about potential adverse effects including dissociative symptoms, hypertension, and confusion/agitation 8, 4
  • In individuals with a history of chronic ketamine use, there have been reports of genitourinary pain that may necessitate cessation of treatment 3
  • Consider discontinuing ketamine if genitourinary pain continues in the setting of other genitourinary symptoms 3

Alternative Routes of Administration

  • While IV administration is the best-studied approach, oral ketamine may offer greater accessibility for some patients 7, 9
  • Oral ketamine has shown efficacy for suicidal ideation at doses of approximately 3 mg/kg, though with more frequent side effects like nausea/vomiting and dissociative symptoms 9

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Efficacy of IV vs. Oral Ketamine for Chronic Pain and Depression

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Ketamine treatment for depression: a review.

Discover mental health, 2022

Guideline

Oral Ketamine Dosing for Depression

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.